(IN BRIEF) Basilea Pharmaceutica Ltd has received an additional USD 5.4 million from BARDA to continue development of its novel oral antibiotic ceftibuten-ledaborbactam etzadroxil. The antibiotic is being developed for complicated urinary tract infections, including pyelonephritis, particularly infections caused by … Read the full press release
Posted in Business, Financial, Government, Healthcare, Investment, Pharma & Biotech, Science, Switzerland, Technology
Tagged Additional BARDA Support Brings Basilea Funding for Ceftibuten-Ledaborbactam to USD 30.8 Million, Administration for Strategic Preparedness and Response, Allschwil, anti-infectives, antimicrobial resistance, ASPR, BARDA, BARDA Awards Further Funding to Basilea for Ceftibuten-Ledaborbactam Development, Basilea, Basilea Advances Oral Antibiotic Candidate for Complicated Urinary Tract Infections, Basilea Pharmaceutica, Basilea Pharmaceutica Ltd, beta lactam beta lactamase inhibitor, Biomedical Advanced Research and Development Authority, BL/BLI, boronic acid beta-lactamase inhibitor, BSLN, carbapenemases, ceftibuten, ceftibuten ledaborbactam etzadroxil, ceftibuten-ledaborbactam, cephalosporinases, complicated urinary tract infections, Cresemba®, cUTI, David Veitch, Enterobacterales, ESBL, extended spectrum beta-lactamases, Fast Track Designation, fungal infections, Gram-negative bacteria, investigational drug, KPC, ledaborbactam, ledaborbactam etzadroxil, multidrug resistant bacteria, non-dilutive funding, novel oral antibiotic, oral cephalosporin, OXA-48, pyelonephritis, QIDP designation, Qualified Infectious Disease Product, Severe Bacterial Infections, SIX Swiss Exchange, Switzerland, U.S Department of Health and Human Services, U.S. FDA, USD 172 million contract potential, USD 30.8 million total funding, USD 5.4 million funding, Zevtera®
(IN BRIEF) Basilea Pharmaceutica has partnered with INCATE, the European incubator for antibacterial therapies, to support the advancement of early-stage anti-infective innovations. As an industry partner, Basilea brings deep expertise in antibacterial and antifungal drug development, while expanding INCATE’s scope … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Non Profit, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged anti-infectives, antibacterial therapies, antifungal therapies, antimicrobial resistance, Basel life sciences, Basilea Joins INCATE to Advance Early-Stage Antibacterial and Antifungal Innovation in Europe, Basilea Pharmaceutica, biopharmaceutical innovation, clinical development, drug development, INCATE, industry partnership, infectious diseases, invasive fungal infections, Laurenz Kellenberger, preclinical research, Primo Schär, University of Basel
(IN BRIEF) Sandoz, a global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas. This acquisition will reinforce Sandoz’s hospital … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?